A Medical Device Daily

Freescale Semiconductor (Orlando) and Monebo Technologies (Austin, Texas) have forged a partnership to deliver a comprehensive platform for medical equipment using electrocardiogram (ECG) technology.

The "ECG-on-a-chip" solution combines Monebo's Kinetic ECG software with Freescale's embedded processing technology to enable medical equipment manufacturers to develop easy-to-use ECG monitoring tools.

"Based on our unique software algorithms and Freescale's processing platforms, we have the technology to provide detailed information to the clinician, enabling physicians to monitor heart patients from a remote location and also analyze and interpret ECG data from any device, including those used for pharmaceutical clinical trials," said Dale Misczynski, president/CEO of Monebo Technologies.

"Individuals affected by many forms of cardiovascular disease often go untreated, as they're either unaware they have the condition or have misgivings about traditional treatments available," said Jose Fernandez Villasenor, MD, global medical applications specialist at Freescale. "Breakthrough silicon and software technologies from companies like Freescale and Monebo are making it easier and more cost-effective to monitor heart patients using a critical and widely understood test – the ECG."

To help healthcare professionals assess cardiac parameters, Monebo Technologies has developed the Kinetic ECG algorithm, which enables signal processing and interpretation of the ECG waveform. The algorithm provides highly accurate QRS (Q wave, R wave and S wave) detection and feature extraction, beat classification, interval measurement and rhythm interpretation for up to 16 leads of captured ECG data.

Monebo's Kinetic software runs on a broad range of Freescale microprocessors and microcontrollers. These processing platform options give developers freedom of choice for their ECG applications, based on their performance, operating power, integration and system cost needs.

In other agreement news:

InTouch Technologies (Santa Barbara, California) reported that it has signed an agreement with Neurostar Solutions (NSI; Atlanta) to integrate NSI's clinical image management application into the company's telestroke offering.

Under terms of the agreement, InTouch Health will incorporate NSI's Internet-based clinical image management application into StrokeRESPOND, a software module integrated into its RP-7 Remote Presence Robotic System.

StrokeRESPOND has been designed to support urgent stroke consults by enabling a stroke expert to have timely access to the information needed to render efficient and informed care decisions for a stroke patient. Through this agreement with NSI, stroke experts will now be able to have access to the patient imaging information needed for stroke diagnosis and treatment.

Advanced Medical Isotope (AMIC; Kennewick, Washington) said it has entered into an agreement to further develop a brachytherapy treatment with Battelle (Columbus, Ohio), which operates the Pacific Northwest National Laboratory, and the department of pharmaceutics and pharmaceutical chemistry at the University of Utah (Salt Lake City).

AMIC proposes development of a concept for controlled delivery of yttrium-90 (Y-90) microspheres embedded in resorbable seed-shape materials for tissue-directed, high-dose intra-tumoral therapy. Use of Y-90 will help to minimize the radiation dose to nearby normal tissues compared to X-rays from standard seeds. This technology is designed to improve the treatment of confined or non- resectable tumors and is based on a fast-dissolving polymer-matrix chemistry.

AxoGen (Alachua, Florida) reported signing a tissue-recovery partnership with American Tissue Services Foundation (ATSF; Overland Park, Kansas). As a result of the partnership, ATSF will offer families the opportunity to donate peripheral nerves, which facilitate communication of signals between the brain and other parts of the body.

Avance Nerve Graft (ANG) is a peripheral nerve repair option that is comprised of donated human peripheral nerve tissue. With more than 100 implants, ANG has enabled recovery in patients with peripheral nerve injuries since 2007, giving surgeons the ability to repair damaged peripheral nerves with allograft nerve without the need for a secondary surgical site and without the need for immunosuppressive medications.